Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 663-673

  Chen, Kai ^a   Al Aowad, Ayman F ^a   Adelstein, S James ^a   Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2',4' DIHYDROXYPHENYL) 6 IODO 4(3H) QUINAZOLINONE I 125; 2 (2',4' DIHYDROXYPHENYL) 6 IODO 4(3H) QUINAZOLINONE I 127; ALKALINE PHOSPHATASE PLACENTA ISOENZYME; AMMONIUM 2 (2',4' DIPHOSPHORYLOXYPHENYL) 6 IODO 4(3H) QUINAZOLINONE; AMMONIUM 2 (2',4' DIPHOSPHORYLOXYPHENYL) 6 IODO 4(3H) QUINAZOLINONE I 125; IODINE; IODINE 125; PRODRUG; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEVICE; DRUG DESIGN; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IODINATION; ISOTOPE LABELING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN STRUCTURE;

ALKALINE PHOSPHATASE; ANIMALS; AUTORADIOGRAPHY; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; HYDROLYSIS; IODINE ISOTOPES; IODINE RADIOISOTOPES; LIGANDS; MICE; MODELS, MOLECULAR; PLACENTA; PRODRUGS; QUINAZOLINONES; SOLUBILITY; SOLUTIONS; TISSUE DISTRIBUTION;

EID: 33847356832     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060944k     Document Type: Article

References (49)

1. Denny, W. A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. 2004, 22, 604-619.
2. Philpott, G. W.; Shearer, W. T.; Bower, R. J.; Parker, C. W. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J. Immunol. 1973, 111, 921-929.
3. Antoniw, P.; Springer, C. J.; Bagshawe, K. D.; Searle, F.; Melton, R. G.; Rogers, G. T.; Burke, P. J.; Sherwood, R. F. Disposition of the prodrug 4-(bis(2-chloroethyl)amino)benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer 1990, 62, 909-914.
4. Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Wilman, D. E. V. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des. 1991, 6, 467-479.
5. Bagshawe, K. D. Antibody-directed enzyme prodrug therapy. Clin. Pharmacokinet. 1994, 27, 368-376.
6. Senter, P. D.; Schreiber, G. J.; Hirschberg, D. L.; Ashe, S. A.; Hellström, K. E.; Hellström, I. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 1989, 49, 5789-5792.
7. Melton, R. G.; Sherwood, R. F. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 1996, 88, 153-165.
8. Cheng, T.-L.; Chen, B.-M.; Chern, J.-W.; Wu, M.-F.; Roffler, S. R. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjugate Chem. 2000, 11, 258-266.
9. Greco, O.; Dachs, G. U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 2001, 187, 22-36.
10. Breistøl, K.; Hendriks, H. R.; Berger, D. P.; Langdon, S. P.; Fiebig, H. H.; Fodstad, Ø. The antitumour activity of the prodrug N-L-leucyldoxorubicin and its parent compound doxorubicin in human tumour xenografts. Eur. J. Cancer 1998, 34, 1602-1606.
11. DeFeo-Jones, D.; Garsky, V. M.; Wong, B. K.; Feng, D.-M.; Bolyar, T.; Haskell, K.; Kiefer, D. M.; Leander, K.; McAvoy, E.; Lumma, P. K.; Wai, J.; Senderak, E. T.; Motzel, S. L.; Keenan, K.; Van Zwieten, M.; Lin, J. H.; Freidinger, R.; Huff, J.; Oliff, A.; Jones, R. E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nature Med. 2000, 6, 1248-1252.
12. Wong, B. K.; DeFeo-Jones, D.; Jones, R. E.; Garsky, V. M.; Feng, D.-M.; Oliff, A.; Chiba, M.; Ellis, J. D.; Lin, J. H. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab. Dispos. 2001, 29, 313-318.
13. Kassis, A. I.; Harapanhalli, R. S. Methods for tumor diagnosis and therapy. U.S. Patent Appl. 09/839,779, 2001.
14. Ho, N.; Harapanhalli, R. S.; Dahman, B. A.; Chen, K.; Wang, K.; Adelstein, S. J.; Kassis, A. I. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjugate Chem. 2002, 13, 357-364.
15. Chen, K.; Wang, K.; Kirichian, A. M.; Al Aowad, A. F.; Iyer, L. K.; Adelstein, S. J.; Kassis, A. I. In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy. Mol. Cancer Ther. 2006, 5, 3001-3013.
16. Pospisil, P.; Wang, K.; Al Aowad, A. F.; Iyer, L. K.; Adelstein, S. J.; Kassis, A. I. Computational modeling, synthesis, and evaluation of a novel prodrug for targeting the extracellular space of prostate tumors. Cancer Res., in press.
17. Wang, K.; Adelstein, S. J.; Kassis, A. I. Evaluation of chemical, physical and biologic properties of a potential anti-tumor radioiodinated quinazolinone derivative. Bioconjugate Chem., in press.
18. Herz, F. Alkaline phosphatase isozymes in cultured human cancer cells. Experientia 1985, 41, 1357-1361.
19. Harris, H. The human alkaline phosphatases: what we know and what we don't know. Clin. Chim. Acta 1990, 186, 133-150.
20. Byers, D. A.; Fernley, H. N.; Walker, P. G. Studies on alkaline phosphatase: catalytic activity of human-placental alkaline-phosphatase variants. Eur. J. Biochem. 1972, 29, 205-209.
21. McComb, R. B.; Bowers, G. N., Jr. Alkaline phosphatase and the International Clinical Enzyme Scale. Am. J. Clin. Pathol. 1985, 84, 67-73.
22. Le Du, M. H.; Stigbrand, T.; Taussig, M. J.; Ménez, A.; Stura, E. A. Crystal structure of alkaline phosphatase from human placenta at 1.8 Å resolution: implication for a substrate specificity. J. Biol. Chem. 2001, 276, 9158-9165.
23. Suzuki, H.; Iino, S.; Endo, Y.; Torii, M.; Miki, K.; Oda, T. Tumor-specific alkaline phosphatase in hepatoma. Ann. N. Y. Acad. Sci. 1975, 259, 307-320.
24. Miyayama, H.; Doellgast, G. J.; Memoli, V.; Gandbhir, L.; Fishman, W. H. Direct immunoperoxidase staining for Regan isoenzyme of alkaline phosphatase in human tumor tissues. Cancer 1976, 38, 1237-1246.
25. Benham, F.; Cottell, D. C.; Franks, L. M.; Wilson, P. D. Alkaline phosphatase activity in human bladder tumor cell lines. J. Histochem. Cytochem. 1977, 25, 266-274.
26. Benham, F. J.; Povey, M. S.; Harris, H. Placental-like alkaline phosphatase in malignant and benign ovarian tumors. Clin. Chim. Acta 1978, 86, 201-215.
27. Benham, F. J.; Harris, H. Human cell lines expressing intestinal alkaline phosphatase. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 4016-4019.
28. Fishman, W. H.; Inglis, N. I.; Stolbach, L. L.; Krant, M. J. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res. 1968, 28, 150-154.
29. Dempo, K.; Elliott, K. A. C.; Desmond, W.; Fishman, W. H. Demonstration of gamma-glutamyl transferase, alkaline phosphatase, CEA and HCG in human lung cancer. Oncodev. Biol. Med. 1981, 2, 21-37.
30. Nouwen, E. J.; Pollet, D. E.; Schelstraete, J. B.; Eerdekens, M. W.; Hänsch, C.; Van de Voorde, A.; De Broe, M. E. Human placental alkaline phosphatase in benign and malignant ovarian neoplasia. Cancer Res. 1985, 45, 892-902.
31. Nouwen, E. J.; Pollet, D. E.; Eerdekens, M. W.; Hendrix, P. G.; Briers, T. W.; De Broe, M. E. Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res. 1986, 46, 866-876.
32. Wick, M. R.; Swanson, P. E.; Manivel, J. C. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum. Pathol. 1987, 18, 946-954.
33. Alberts, I. L.; Nadassy, K.; Wodak, S. J. Analysis of zinc binding sites in protein crystal structures. Protein Sci. 1998, 7, 1700-1716.
34. Buzko, O. V.; Bishop, A. C.; Shokat, K. M. Modified AutoDock for accurate docking of protein kinase inhibitors. J. Comput. Aided Mol. Des. 2002, 16, 113-127.
35. Hu, X.; Shelver, W. H. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. J. Mol. Graph. Model. 2003, 22, 115-126.
36. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
37. Tuttle, C. T. T.; Seabrook, S. A.; Wise, L. E.; Katsifis, A.; Knott, R. B.; Yates, B. F. Molecular modelling and design of radiolabelled complexes for melanoma diagnosis. Aust. J. Chem. 2004, 57, 87-96.
38. Llinas, P.; Stura, E. A.; Ménez, A.; Kiss, Z.; Stigbrand, T.; Millán, J. L.; Le Du, M. H. Structural studies of human placental alkaline phosphatase in complex with functional ligands. J. Mol. Biol. 2005, 350, 441-451.
39. Doellgast, G. J.; Homesley, H. D. Placental-type alkaline phosphatase in ovarian cancer fluids and tissues. Obstet. Gynecol. 1984, 63, 324-329.
40. Epenetos, A. A.; Travers, P.; Gatter, K. C.; Oliver, R. D. T.; Mason, D. Y.; Bodmer, W. F. An immunohistological study of testicular germ cell tumours using two different monoclonal antibodies against placental alkaline phosphatase. Br. J. Cancer 1984, 49, 11-15.
41. McDicken, I. W.; McLaughlin, P. J.; Tromans, P. M.; Luesley, D. M.; Johnson, P. M. Detection of placental-type alkaline phosphatase in ovarian cancer. Br. J. Cancer 1985, 52, 59-64.
42. Pollet, D. E.; Nouwen, E. J.; Schelstraete, J. B.; Renard, J.; Van de Voorde, A.; De Broe, M. E. Enzyme-antigen immunoassay for human placental alkaline phosphatase in serum and tissue extracts, and its application as a tumor marker. Clin. Chem. 1985, 31, 41-45.
43. Wang, K.; Adelstein, S. J.; Kassis, A. I. Radiotracer-based method for determining water solubility of highly insoluble compounds. J. Label. Compd. Radiopharm. 2006, 49, 773-788.
44. Guex, N.; Peitsch, M. C. SWISS-MODEL and the Swiss-Pdb viewer: an environment for comparative protein modeling. Electrophoresis 1997, 18, 2714-2723.
45. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S., Jr.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106, 765-784.
46. Accelrys Software Incorporated. http://www.accelrys.com/products/insight/ .
47. Fujitsu America Incorporated, CAChe 5.0. http://www.cachesoftware.com/ cache/index.shtml.
48. Stote, R. H.; Karplus, M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 1995, 23, 12-31.
49. OriginLab Corporation Origin 7.0. http://www.originlab.com/.